Stock ITOS ITEOS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
17.4 USD +3.51% Intraday chart for iTeos Therapeutics, Inc. +0.35% +58.90%
May. 13 HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating MT
May. 10 Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ITeos Therapeutics Announces $120 Million Registered Direct Offering
AQ
ITeos Reports First Quarter 2024 Financial Results and Provides Business Updates
AQ
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $46 From $44, Maintains Buy Rating
MT
ITeos Therapeutics : SECURITIES PURCHASE AGREEMENT - Form 8-K
PU
Wedbush Adjusts iTeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating
MT
ITeos Therapeutics Q1 Net Loss Widens; Initiates $120 Million Registered Direct Offering -- Shares Jump
MT
ITeos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
ITeos Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
ITeos Therapeutics Announces $120 Million Registered Direct Offering
GL
ITeos Therapeutics Announces $120 Million Registered Direct Offering
AQ
ITeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
AQ
ITeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
GL
Top Premarket Decliners
MT
JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating
MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating
MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
ITeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
GL
ITeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
GL
ITeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
AQ
ITeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ITOS Stock
  4. News iTeos Therapeutics, Inc.